Edgewise Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Edgewise Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-47.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 71% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-141.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 88% of Healthcare companies in United States.
Cash Cushion Ratio
+12%Cash, after subtracting all debt, equals 12% of its market value (net cash).
Higher than 53% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Edgewise Therapeutics, Inc. made a loss over the last year. Edgewise Therapeutics, Inc. owes $0.07 for every $1 it owns. Edgewise Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossEdgewise Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
9.53The share price is 9.53 times Edgewise Therapeutics, Inc.'s book value per share, higher than 86% of Healthcare companies in United States.
Market cap
$4.3 BThe total market value of all of Edgewise Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 83% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$448 MWhat Edgewise Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.13Net worth divided by the number of shares. The share price of $39.31 is 9.5 times this, which is the P/B above.
Return on equity (ROE)
-38.0%Edgewise Therapeutics, Inc. lost 38.0% of its shareholders' money over the last year, higher than 56% of Healthcare companies in United States.
Owes vs Owns
0.07×Edgewise Therapeutics, Inc. owes $0.07 for every $1 it owns (low), lower than 93% of Healthcare companies in United States.
Dividend yield
NoneEdgewise Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossEdgewise Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashEdgewise Therapeutics, Inc. held $526 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Edgewise Therapeutics, Inc.: $4.3 B ÷ $448 M (30 Jun 2026) = 9.5.
What is Edgewise Therapeutics, Inc.'s return on equity?
Edgewise Therapeutics, Inc. lost 38.0% of its shareholders' money over the last year, higher than 56% of Healthcare companies in United States.
How much does Edgewise Therapeutics, Inc. owe compared with what it owns?
Edgewise Therapeutics, Inc. owes $0.07 for every $1 it owns (low), lower than 93% of Healthcare companies in United States.
Does Edgewise Therapeutics, Inc. pay a dividend?
No. Edgewise Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.